"Designing Growth Strategies is in our DNA"
Renal replacement therapies performed among patients with improper kidney function include kidney transplant, peritoneal dialysis, and hemodialysis. Among them, hemodialysis is a process of purifying blood while removing the waste materials such as urea and creatinine from the body. This helps in the regulation of blood pressure along with managing mineral balance.
Growing prevalence of chronic kidney diseases, end-stage renal disease (ESRD), renal failure, and others across the globe are likely to boost the demand for hemodialysis bloodline systems during the forecast period. Growing research and development activities resulting in the development of innovative products are likely to increase the adoption of the hemodialysis bloodline systems by the physicians. For instance, in April 2018, Fresenius Medical Care AG & Co. KGaA, a leading provider of bloodline systems, won the Red Dot Award for its Product Design for the company’s 6008 CAREset indicating satisfactory therapeutic merits.
To gain extensive insights into the market, Request for Customization
The growth in global hemodialysis bloodline market is being driven by the increase in the prevalence of chronic kidney disease (CKD) as well as end-stage renal disease (ESRD), increase in cases of renal complications due to diabetes, improved government-aided health reimbursement. According to the National Chronic Kidney Disease Fact Sheet, in 2017, nearly 30 million U.S. population was estimated to have chronic kidney disease (CKD), which accounted for 15% of the U.S. population. However, the high cost of the overall dialysis process, comparatively less healthcare spending in emerging regions, and lack of healthcare awareness are some of the factors likely to hinder the market growth during the forecast period.
Some of the major companies that are present in the global hemodialysis bloodline systems market are Baxter, B. Braum Melsungen AG, NIPRO, Bioteque Corporation, Allmed Medical Care Holdings Limited, Fresenius Medical Care Australia Pty Ltd, Weigao Group, Sunder Biomedical Tech Co., Ltd., Asahi Kasei Medical Co., Ltd., among others.
SEGMENTATION | DETAILS |
By Product | · Poly Vinyl Chloride (Pvc) Haemodialysis Bloodline Systems · Polyethylene (Pe) Haemodialysis Bloodline Systems · Polypropylene (Pp) Haemodialysis Bloodline Systems · ABS hemodialysis bloodline systems |
By Therapy Type | · Double Needle Therapy · Single Needle Therapy · Single Needle Crossover · Haemodiafiltration |
By End User | · Hospitals · Clinics · Home Care Settings · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) · Latin America (Brazil, Mexico, and Rest of Latin America) · Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa) |
In terms of product, the Poly Vinyl chloride (PVC) hemodialysis bloodline systems are likely to hold major market share owing to its availability and high acceptance due to its affordability. Among end-users, the homecare settings are anticipated to expand at the highest CAGR during the forecast period.
The global hemodialysis bloodline systems market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a considerable share of the global hemodialysis bloodline systems market owing to the high prevalence of chronic kidney diseases. According to the report by World Health Organization (WHO), high-income countries typically spend more than 2–3% of their annual health-care budget on the treatment of end-stage kidney disease, even though those receiving such treatment represent under 0.03% of the total population. Asia Pacific is projected to expand at a significantly high growth rate attributable to a surge in the economy, growing awareness among the population in the region, and expansion of footprints by leading players in the region.
US +1 833 909 2966 ( Toll Free )